Literature DB >> 25411824

Ability of bacteriophage in resolving wound infection caused by multidrug-resistant Acinetobacter baumannii in uncontrolled diabetic rats.

VinodKumar Chickmangalure Shivaswamy1, Suneeta Basavaraj Kalasuramath, Chethan Kumar Sadanand, Abhishek Kilagere Basavaraju, Varsha Ginnavaram, Sumanth Bille, Sanjay Saju Ukken, Usha Nandini Pushparaj.   

Abstract

Acinetobacter baumannii, a substantial nosocomial pathogen, has developed resistance to almost all available antimicrobial drugs. Bacteriophage therapy is a possible alternative treatment for multidrug-resistant (MDR) bacterial infections. In this study, we have successfully isolated bacteriophage active against clinical strains of A. baumannii by enrichment from hospital sewage sludge using representatives of those strains. The bacteriophage isolated against A. baumannii formed plaques against beta-lactamases producing strains of A. baumannii. The utility of bacteriophage specific for A. baumannii to resolve wound infection in uncontrolled diabetic rats was evaluated. Five groups of uncontrolled diabetic rats were used. Group I was noninfected (Control), Group II was infected with MDR A. baumannii and challenged with bacteriophage, Group III was infected with MDR A. baumannii, Group IV was infected with MDR A. baumannii and challenged with antibiotic colistin, and Group V consisted of noninfected rats and sprayed with phage (Phage control). A significant decrease in infection, period of epithelization, and wound contraction was observed in the phage-challenged group when compared with antibiotic-treated uncontrolled diabetic rats and the control group. To conclude the study, new insights are provided into the biology of the broad host range of A. baumannii phage, demonstrating that A. baumannii phage has prospects for the treatment of infections caused by the MDR A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25411824     DOI: 10.1089/mdr.2014.0120

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  14 in total

Review 1.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model.

Authors:  Stephen T Abedon
Journal:  Front Microbiol       Date:  2016-08-10       Impact factor: 5.640

4.  Evaluation of Beneficial Influence of Local Application of Crocus Pallasii Subsp. Haussknechtii Boiss. Extract on Healing of Full Thickness Excisional Infected Wounds in Diabetic Rats.

Authors:  Mohammad Ali Ashja Zadeh; Mohsen Ebrahimi; Amir Ahmad Salarian; Seyyed Reza Abtahi; Alireza Jahandideh
Journal:  Bull Emerg Trauma       Date:  2020-07

Review 5.  Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection.

Authors:  Jiun-Ling Wang; Chih-Feng Kuo; Che-Ming Yeh; Jung-Ren Chen; Ming-Fang Cheng; Chih-Hsin Hung
Journal:  Infect Drug Resist       Date:  2018-11-15       Impact factor: 4.003

6.  A Novel, Highly Related Jumbo Family of Bacteriophages That Were Isolated Against Erwinia.

Authors:  Ruchira Sharma; Brittany A Pielstick; Kimberly A Bell; Tanner B Nieman; Olivia A Stubbs; Edward L Yeates; David A Baltrus; Julianne H Grose
Journal:  Front Microbiol       Date:  2019-07-23       Impact factor: 5.640

7.  Development of Antimicrobial Therapy Methods to Overcome the Antibiotic Resistance of Acinetobacter baumannii.

Authors:  O V Kisil; T A Efimenko; N I Gabrielyan; O V Efremenkova
Journal:  Acta Naturae       Date:  2020 Jul-Sep       Impact factor: 1.845

8.  Characterization and Testing the Efficiency of Acinetobacter baumannii Phage vB-GEC_Ab-M-G7 as an Antibacterial Agent.

Authors:  Ia Kusradze; Natia Karumidze; Sophio Rigvava; Teona Dvalidze; Malkhaz Katsitadze; Irakli Amiranashvili; Marina Goderdzishvili
Journal:  Front Microbiol       Date:  2016-10-04       Impact factor: 5.640

9.  Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) Acinetobacter baumannii and Evaluation of Their Therapeutic Efficacy in Vivo.

Authors:  Kyoungeun Cha; Hynu K Oh; Jae Y Jang; Yunyeol Jo; Won K Kim; Geon U Ha; Kwan S Ko; Heejoon Myung
Journal:  Front Microbiol       Date:  2018-04-10       Impact factor: 5.640

10.  A Novel Phage PD-6A3, and Its Endolysin Ply6A3, With Extended Lytic Activity Against Acinetobacter baumannii.

Authors:  Minle Wu; Kongying Hu; Youhua Xie; Yili Liu; Di Mu; Huimin Guo; Zhifan Zhang; Yingcong Zhang; Dong Chang; Yi Shi
Journal:  Front Microbiol       Date:  2019-01-09       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.